ACLX

NEUTRALM&A

Arcellx, Inc.

2026-04-17

Price

$115.05

-0.04%

Score17.5Top Tier

Signals7/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.5xvs 20d avg

Analysis

Arcellx's (ACLX) technical profile, featuring an exceptionally low 1.8% realized volatility and a 'Quiet Storm' signal, is entirely driven by Gilead's pending acquisition at $115 per share in cash plus a $5 Contingent Value Right (CVR). The stock is effectively pegged to this deal price, explaining the low volume and tight trading range. With the broader macro regime flashing a clear RISK_ON signal and credit markets showing abundant liquidity, the environment is highly supportive of M&A deal closures. Today's news that Gilead has extended the tender offer to April 27 while securing all regulatory approvals reinforces near-term certainty.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUE

Key Takeaways

M&A Arbitrage Play: ACLX is pinned at $115, directly matching Gilead's base cash offer, with potential upside tied to the $5 CVR based on Anito-cel sales [1.3].
Tender Offer Progress: The percentage of tendered shares increased from 7.5% to 18%, and Gilead has extended the deadline to April 27 to secure the required majority.
Regulatory Clearance: Gilead has obtained all necessary regulatory approvals, significantly de-risking the transaction in a highly liquid macro environment.

← Back to 2026-04-17 View Full ACLX History →Yahoo Finance &nearr;